A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
Clinical trial NCT04967625 · UNKNOWN
Trial details
- NCT number
- NCT04967625
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-26
- Primary completion
- 2022-12-31
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.